Upsher-Smith

05/01/2026

A reminder that caring for our minds is just as important as caring for our bodies — and deserves attention all year long.

04/15/2026

Upsher-Smith is pleased to share new digital resources designed to support individuals living with Duchenne muscular dystrophy and the families and clinicians who care for them.

Our KYMBEE™ (deflazacort) Tablets caregiver and healthcare professional websites offer practical guidance on treatment access, helpful tools for caregivers, prescribing resources for clinicians, and information about the Promise of Support® Program.

Designed with the Duchenne community in mind, these platforms strive to provide access to trusted information quickly and confidently.

Click here to learn more: https://bit.ly/42euVOs

SELECT IMPORTANT SAFETY INFORMATION

KYMBEE (deflazacort) Tablets are a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE.

Please see additional safety information: https://bit.ly/4tewBU3

And full Prescribing information: https://bit.ly/4sVyGUh

04/06/2026

Upsher-Smith has launched Ciprofloxacin [0.3%] and Dexamethasone [0.1%] Otic Suspension.

Learn more about our first prescription ear drop suspension and its availability by clicking below:

Read this post on the Upsher-Smith website.

03/30/2026

Honoring the physicians whose dedication drives progress in healthcare.

Your leadership and expertise make a profound impact on patients and communities. Today, we say thank you.

03/09/2026

It’s National Patient Safety Awareness Week — a moment to spotlight the care and vigilance patients deserve. At Upsher-Smith, safety drives every decision we make.

Putting patients first, today and every day.

02/28/2026

At Upsher-Smith, we are dedicated to driving awareness and offering treatment options for patients with rare diseases. Our specialized programs support patients with infantile spasms (IS), Duchenne muscular dystrophy (DMD), and other rare conditions, helping to support patients and their families.

02/24/2026

Did you know that Upsher‑Smith offers a number of heart‑related generics, including therapies used to help manage blood pressure, cholesterol, heart‑rhythm conditions, and electrolyte support?

This Heart Health Month, learn more about our product portfolio here: https://lnkd.in/gCPXqWav

Nothing beats a healthy heart!

02/20/2026

Caregivers play an essential role in the health of families and communities.

Today, on National Caregivers Day, Upsher-Smith recognizes your unwavering commitment and the impact you make every day. We’re proud to contribute to your efforts by delivering medicines that help support patients.

01/12/2026

Happy National Pharmacist Day! Today we celebrate pharmacists for their expertise, compassion, and dedication to improving patient health. At Upsher-Smith, we are grateful for the vital role pharmacists play in supporting communities and advancing care.



Image credit bzzrincantation

12/19/2025

Wonderful news, and a pivotal moment in the fight against Duchenne muscular dystrophy.

🎉 Today, we’re celebrating an exciting milestone for the community: Duchenne has been added to the Recommended Uniform Screening Panel (RUSP)!

By reducing the diagnostic delays that have affected Duchenne families for generations, early identification through can:
- Allow families to connect with care and neuromuscular experts sooner
- Access approved therapies and supportive interventions earlier
- Improve long-term health outcomes

💪This milestone is a testament to the power of collaboration and this community’s shared commitment to ensuring every child with Duchenne, regardless of zip code, has the best possible start in life. Learn more: https://www.prnewswire.com/news-releases/us-department-of-health-and-human-services-adds-duchenne-to-recommended-uniform-screening-panel-302643725.html?tc=eml_cleartime

Muscular Dystrophy Association

12/03/2025

FACT: Every 12 minutes, a child is diagnosed with infantile spasms worldwide, with onset typically between 3 and 8 months. These seizures are rare but serious, and without prompt diagnosis and treatment, they can lead to developmental delays and brain damage.

This December (Dec 1–7), during Infantile Spasms Awareness Week, take a moment to learn the signs. Because when it comes to a baby’s brain, every second matters.

Upsher-Smith is proud to sponsor ISAW and is committed to supporting families affected by IS.

Learn more about the signs and symptoms at infantilespasms.org.

12/03/2025

Upsher-Smith is proud to announce the launch of KYMBEE™ (deflazacort) Tablets.

KYMBEE™ is the only deflazacort backed by Upsher-Smith’s Promise of Support® Program designed to assist families throughout their treatment journey.

Learn more here: https://bit.ly/4ow8a1q